Barclays Begins Coverage on Amneal Pharmaceuticals (NASDAQ:AMRX)

Investment analysts at Barclays started coverage on shares of Amneal Pharmaceuticals (NASDAQ:AMRX) in a research note issued to investors on Monday, Marketbeat reports. The brokerage set an “overweight” rating and a $15.00 price target on the stock. Barclays‘s price target points to a potential upside of 25.31% from the company’s previous close.

Several other equities analysts have also issued reports on AMRX. Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, October 8th. Piper Sandler restated an “overweight” rating and set a $13.00 price objective (up previously from $11.00) on shares of Amneal Pharmaceuticals in a report on Friday, October 31st. Finally, JPMorgan Chase & Co. upped their target price on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Amneal Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $13.50.

Amneal Pharmaceuticals Stock Performance

Shares of Amneal Pharmaceuticals stock opened at $11.97 on Monday. The firm has a fifty day moving average of $11.12 and a two-hundred day moving average of $9.50. The stock has a market capitalization of $3.76 billion, a price-to-earnings ratio of 598.80 and a beta of 1.36. Amneal Pharmaceuticals has a 52 week low of $6.68 and a 52 week high of $12.68.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.05. The business had revenue of $784.51 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 185.60% and a net margin of 0.20%.Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. As a group, research analysts forecast that Amneal Pharmaceuticals will post 0.53 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Ted C. Nark sold 50,000 shares of the stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $11.72, for a total transaction of $586,000.00. Following the completion of the sale, the director directly owned 291,029 shares of the company’s stock, valued at approximately $3,410,859.88. This represents a 14.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Nikita Shah sold 131,856 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $11.92, for a total transaction of $1,571,723.52. Following the sale, the executive vice president owned 146,403 shares in the company, valued at $1,745,123.76. This trade represents a 47.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 231,856 shares of company stock valued at $2,743,724. 17.45% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Amneal Pharmaceuticals by 6.2% in the 1st quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company’s stock worth $132,092,000 after purchasing an additional 920,758 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Amneal Pharmaceuticals by 14.8% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,767,594 shares of the company’s stock valued at $14,812,000 after purchasing an additional 227,660 shares during the period. Deutsche Bank AG lifted its holdings in shares of Amneal Pharmaceuticals by 128.3% in the first quarter. Deutsche Bank AG now owns 305,621 shares of the company’s stock valued at $2,561,000 after purchasing an additional 171,735 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of Amneal Pharmaceuticals in the first quarter valued at about $31,000. Finally, Invesco Ltd. boosted its position in shares of Amneal Pharmaceuticals by 19.2% during the first quarter. Invesco Ltd. now owns 2,272,713 shares of the company’s stock worth $19,045,000 after buying an additional 365,467 shares during the period. 31.82% of the stock is owned by institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.